TABLE 1.
Group | Lymphoma
|
Erythroblastosis
|
Myelocytomatosis
|
Sarcoma
|
Adenocarcinoma
|
|||||
---|---|---|---|---|---|---|---|---|---|---|
No. (%) | MTD (days) | No. (%) | MTD (days) | No. (%) | MTD (days) | No. (%) | MTD (days) | No. (%) | MTD (days) | |
RCASBP(A)-myc + RCASBP(B)-bic (n = 39) | 15 (38.5) | 27.5b | 4 (10.3)c | 32.5d | 5 (12.8)e | 44.5 | 7 (18.0) | 58.0 | 6 (15.4) | 51.2 |
RCASBP(A)-myc + RCASBP(B) (n = 42) | 13 (31.0) | 53.0 | 0 (0.0) | — | 18 (42.9)f | 51.8 | 10 (23.8) | 65.8 | 11 (26.2) | 62.0 |
RCASBP(A) + RCASBP(B)-bic (n = 20) | 10 (50.0) | 99.5 | 3 (15.0) | 94.5 | 0 (0.0) | — | 1 (5.0) | 65.5 | 0 (0.0) | — |
RCASBP(A) + RCASBP(B) (n = 8) | 2 (25.0) | 96.5 | 0 (0.0) | — | 0 (0.0) | — | 0 (0.0) | — | 0 (0.0) | — |
Data are number (percent) of animals. MTD, median time to death.
P < 0.05 versus other three groups.
P < 0.05 versus the RCASBP(A)-myc plus RCASBP(B) group.
P < 0.05 versus the RCASBP(A) plus RCASBP(B)-bic group.
P < 0.01 versus the RCASBP(A)-myc plus RCASBP(B) group.
P < 0.05 versus the RCASBP(A) plus RCASBP(B) group.